New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
12:18 EDTT, PRAN, NDZ, TEVA, MNTA, MYL, MUOn The Fly: Midday Wrap
Stocks on Wall Street were higher at midday in the last trading day of the first quarter of the year. The disappointing Chicago purchasing managers' report was offset by dovish comments from Fed Chief Yellen, who said the the central bank’s "extraordinary" aid will last for "some time.” ECONOMIC EVENTS: In the U.S., the Chicago PMI business barometer index came in at 55.9, versus the consensus forecast for a 59.0 reading. In Europe, the annual inflation rate across the 18-country eurozone fell for the third consecutive month, slipping to 0.5% in March, compared to analysts' consensus forecast for a milder drop to 0.6%. COMPANY NEWS: Shares of AT&T (T) advanced early in the session after the company's board of directors authorized the repurchase of up to 300M shares, or about 6% of its common shares outstanding. The company also noted it has 125M shares left under its buyback authorization that was issued in March of last year, but the stock had given up much of its early advance to be up fractionally near noon. MAJOR MOVERS: Among the notable gainers was Canada's Nordion (NDZ), which jumped 11% after the company agreed to be acquired by Sterigenics for $11.75 per share in cash shortly after Canada's government lifted its 25% limit on foreign investment in the company. Also higher following analyst commentary was Micron (MU), which rose nearly 8% amid notes in its defense from Stifel and Pacific Crest, as well as broad-based strength in technology stocks that have recently pulled back. Among the noteworthy losers were Momenta Pharmaceuticals (MNTA), which dropped 15%, and Mylan (MYL), which slipped over 1%, after the Supreme Court agreed to hear an appeal by Teva (TEVA) of a court ruling that would enable generic versions of its multiple sclerosis drug, Copaxone, to be sold in May. Also lower were shares of Prana Biotechnology (PRAN), which plunged over 70% after its clinical study of a drug being tested as a treatment of Alzheimer's Disease did not hit its primary endpoint. INDEXES: Near midday, the Dow was up 118.43, or 0.73%, to 16,441.49, the Nasdaq was up 52.48, or 1.26%, to 4,208.23, and the S&P 500 was up 14.56, or 0.78%, to 1,872.18.
News For T;PRAN;NDZ;TEVA;MNTA;MYL;MU From The Last 14 Days
Check below for free stories on T;PRAN;NDZ;TEVA;MNTA;MYL;MU the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
July 14, 2014
10:34 EDTTAT&T joint venture acquires Creativebug from Demand Media for $10M
Otter Media, a joint venture between AT&T (T) and The Chernin Group, has acquired Creativebug from Demand Media (DMD), the companies announced earlier. Creativebug offers do-it-yourself video workshops featuring instruction from artists and designers. Demand Media confirmed in a regulatory filing earlier that it completed the sale of substantially all of the assets relating to its Creativebug business for $10.0M in cash. AT&T and The Chernin Group announced the formation of the joint venture to acquire, invest in and launch over-the-top video services previously on April 22.
09:45 EDTMYLMylan moves higher, levels to watch
Abbott (ABT) sold its developed markets generics pharmaceuticals business to Mylan (MYL), which is sending shares of the latter higher to $51.83. At that price next resistance is at $53, the session high. Support is at $50.88.
09:31 EDTTAT&T, EPIX reach carriage agreement
Subscribe for More Information
09:16 EDTMYLOn The Fly: Pre-market Movers
HIGHER: Citigroup (C), up 3.6% after reporting better than expected Q2 results, announcing $7B settlement with DOJ and FDIC... Apple (AAPL), up 0.7% after Barclays upgrades stock to Overweight, Morgan Stanley raises Apple estimates above consensus... Shire (SHPG), up 1.6% after receiving revised proposal from AbbVie (ABBV) of GPB 53.20 per share, which it says it would be willing to recommend to Shire shareholders. AbbVie is down 2.8% after the news... Mylan (MYL), up 4% after acquiring Abbott's (ABT) non-U.S. developed markets specialty and branded generics business in all-stock transaction valued at about $5.3B. Abbott up 1.6% after the news... Progenics (PGNX), up 13% after FDA says RELISTOR can be approved on data submitted in sNDA... Exelixis (EXEL), up 13% after announcing coBRIM Phase 3 trial met primary endpoint... URS (URS) up 8% after acquired by AECOM Technology (ACM) for $56.31 per share. AECOM shares alos up 2% after deal announcement... Whiting Petroleum (WLL), up 4.5% after agreeing to acquire Kodiak Oil & Gas (KOG) in a $6B transaction. Kodiak Oil & Gas up 3%... Kandi Technologies (KNDI), up 11% after announcing JV's sale of 4,114 EVs in Q2. LOWER: Riverbed (RVBD), down 4.5% after saying it sees its Q2 adjusted EPS at low end of 26c-28c range... Harmonic (HLIT), down 13% after reporting preliminary Q2 earnings results.. EBay (EBAY), down 0.5% after downgraded at Pacific Crest, confirming partnership plans with Sotheby's (BID).
08:55 EDTMYLMylan says does not anticipate regulatory hurdles prohibiting close of deal
08:49 EDTMYLMylan says Abbott assets unlike other mature generic drug portfolios
Subscribe for More Information
08:36 EDTMYLMylan accretive tax inversion deal makes sense, says UBS
Subscribe for More Information
08:32 EDTTSynchronoss acquires Voxmobili for $26M in cash
Synchronoss (SNCR) announced its acquisition of Voxmobili, a wholly owned subsidiary of OnMobile Global. Voxmobili’s customers include AT&T (T), Airtel, Everything Everywhere, France Telecom, Orange (ORAN), T-Mobile (TMUS), and Vodafone (VOD). In consideration for the acquisition, Synchronoss paid approximately $26M in cash to OnMobile Global.
08:27 EDTMYLMylan sees Abbott transaction to be 'immediately and significantly accretive'
Subscribe for More Information
08:26 EDTMYLMylan sees $10B in pro forma 2014 sales after closing Abbott deal
Subscribe for More Information
08:12 EDTMYLMylan says Abbott deal 'first in series' of planned transactions
Subscribe for More Information
08:04 EDTTEVATeva announces FDA acceptance of NDA filing for albuterol MDPI
Teva Pharmaceuticals Industries announced that the U.S. Food and Drug Administration has accepted for review the company’s new drug application for albuterol multi-dose dry-powder inhaler, an investigational breath-actuated dry-powder inhaler for the treatment or prevention of bronchospasm in patients 12 years of age and older with reversible obstructive airway disease; and for the prevention of exercise-induced bronchospasm in patients 12 years of age and older. The NDA filing includes data from eight clinical studies that evaluated the safety and efficacy of albuterol MDPI in adults and adolescents with asthma and exercise-induced bronchospasm. The NDA for albuterol MDPI has been accepted by the FDA for standard review, with a FDA Regulatory Action expected in March 2015.
07:28 EDTMYLMylan to host conference call
Subscribe for More Information
07:20 EDTMYLAbbott to host conference call
Conference call to discuss agreement to sell developed markets branded generics pharmaceuticals business to Mylan will be held on July 14 at 9:30 am. Webcast Link
06:54 EDTMYLWhiting Petroleum volatility expected to move on acquisition of Kodiak Oil & Gas
Whiting Petroleum (WLL) option implied volatility is expected to move on the acquisition of Kodiak Oil & Gas (KOG) in an all-stock transaction valued at $6B. Overall option implied volatility of 31 is at its 26-week average according to Track Data, suggesting non-directional price movement.
06:33 EDTMYLAbbott to sell developed markets generics pharmaceuticals business to Mylan
Subscribe for More Information
06:33 EDTMYLMylan to acquire Abbott assets in all-stock transaction valued at about $5.3B
Subscribe for More Information
06:31 EDTMYLAbbott to sell developed markets generics pharmaceuticals business to Mylan
Subscribe for More Information
July 13, 2014
20:22 EDTMYLMylan near buying Europe-based drug portfolio from Abbott, Reuters says
Subscribe for More Information
July 11, 2014
08:07 EDTNDZNordion announces termination of HSR waiting period for Sterigenics acquisition
Nordion announced that on July 10, the Federal Trade Commission terminated the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended with respect to Sterigenics’ proposed acquisition of Nordion and the Canadian Competition Bureau issued a no-action letter pursuant to the Competition Act. The receipt of a no-action letter confirms that the Commissioner of Competition does not intend to challenge the proposed acquisition. The termination of the HSR Act waiting period and the receipt of a no-action letter pursuant to the Competition Act satisfy closing conditions of the proposed acquisition. The transaction remains subject to certain closing conditions, including approval under the Investment Canada Act, and is expected to close in 2H14.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use